Is RENAL FAILURE ACUTE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed RENAL FAILURE ACUTE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 69 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported RENAL FAILURE ACUTE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and RENAL FAILURE ACUTE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause RENAL FAILURE ACUTE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes RENAL FAILURE ACUTE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if RENAL FAILURE ACUTE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing RENAL FAILURE ACUTE: 69
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where RENAL FAILURE ACUTE is a reported side effect: 2.0727%

FDA reports of any drug causing RENAL FAILURE ACUTE : 48309
Average percentage for all medicated patients where RENAL FAILURE ACUTE is reported as a complication: 0.3028%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with RENAL FAILURE ACUTE:

ASPIRIN (5759 patients)
LASIX (4194 patients)
HEPARIN SODIUM INJECTION (3837 patients)
FUROSEMIDE (3660 patients)
LISINOPRIL (2893 patients)
METFORMIN HCL (2834 patients)
SIMVASTATIN (2473 patients)
OMEPRAZOLE (2423 patients)
ALLOPURINOL (2308 patients)
DIGOXIN (1970 patients)
ACETAMINOPHEN (1965 patients)
LIPITOR (1943 patients)
ATENOLOL (1800 patients)
PREDNISONE (1752 patients)
ZOCOR (1691 patients)
RAMIPRIL (1660 patients)
FOSAMAX (1624 patients)
TRASYLOL (1622 patients)
PLAVIX (1554 patients)
VIOXX (1509 patients)
IBUPROFEN (1494 patients)
VANCOMYCIN (1478 patients)
POTASSIUM CHLORIDE (1458 patients)
NEXIUM (1438 patients)
COUMADIN (1432 patients)
HYDROCHLOROTHIAZIDE (1426 patients)
AMLODIPINE (1423 patients)
NORVASC (1409 patients)
LEVOTHYROXINE SODIUM (1399 patients)
METHOTREXATE (1353 patients)
SPIRONOLACTONE (1306 patients)
FOLIC ACID (1288 patients)
DEXAMETHASONE (1244 patients)
INSULIN (1216 patients)
REVLIMID (1209 patients)
ALDACTONE (1208 patients)
ZOMETA (1185 patients)
PREDNISOLONE (1171 patients)
WARFARIN SODIUM (1170 patients)
CISPLATIN (1129 patients)
PROTONIX (1107 patients)
LANTUS (1083 patients)
HEPARIN (1071 patients)
ENALAPRIL MALEATE (1068 patients)
GLUCOPHAGE (1053 patients)
CRESTOR (1028 patients)
SEROQUEL (1015 patients)
VALTREX (977 patients)
METOPROLOL TARTRATE (959 patients)
NITROGLYCERIN (930 patients)
SYNTHROID (910 patients)
DIOVAN (902 patients)
NEURONTIN (893 patients)
CYCLOSPORINE (869 patients)
METFORMIN (855 patients)
BISOPROLOL FUMARATE (847 patients)
COREG (843 patients)
LORAZEPAM (830 patients)
MORPHINE (820 patients)
PRILOSEC (820 patients)
ALBUTEROL (818 patients)
ACYCLOVIR (811 patients)
CIPROFLOXACIN (808 patients)
GABAPENTIN (790 patients)
LANSOPRAZOLE (783 patients)
XANAX (777 patients)
VELCADE (764 patients)
LOVENOX (758 patients)
TOPROL-XL (746 patients)
ZOFRAN (740 patients)
PREDNISONE TAB (740 patients)
LYRICA (739 patients)
ALTACE (739 patients)
FENTANYL (735 patients)
FLUCONAZOLE (732 patients)
BACTRIM (730 patients)
REMICADE (724 patients)
AMBIEN (724 patients)
CARVEDILOL (719 patients)
LEVAQUIN (719 patients)
FLUOROURACIL (715 patients)
OXYCONTIN (697 patients)
METOPROLOL (692 patients)
ATIVAN (675 patients)
VOLTAREN (672 patients)
CYCLOPHOSPHAMIDE (670 patients)
ATORVASTATIN CALCIUM (666 patients)
PROGRAF (661 patients)
CELEBREX (650 patients)
AMOXICILLIN (639 patients)
TRAMADOL HCL (635 patients)
AMIODARONE HCL (632 patients)
TORSEMIDE (619 patients)
OXYCODONE HCL (615 patients)
AVANDIA (606 patients)
BYETTA (605 patients)
PANTOPRAZOLE (605 patients)
METFORMIN HYDROCHLORIDE (604 patients)
CARBOPLATIN (602 patients)
CORDARONE (595 patients)
NEORAL (589 patients)
COZAAR (584 patients)
LOPRESSOR (584 patients)
HEPARIN SODIUM (583 patients)
FERROUS SULFATE TAB (582 patients)
PANTOPRAZOLE SODIUM (581 patients)
GLYBURIDE (574 patients)
ATORVASTATIN (572 patients)
MORPHINE SULFATE (571 patients)
MYCOPHENOLATE MOFETIL (568 patients)
PREVACID (561 patients)
ALPRAZOLAM (560 patients)
METOCLOPRAMIDE (556 patients)
DECADRON (556 patients)
VITAMIN D (553 patients)
GLIPIZIDE (552 patients)
PROPOFOL (551 patients)
VICODIN (550 patients)
KALETRA (546 patients)
TRUVADA (544 patients)
ACETYLSALICYLIC ACID SRT (535 patients)
HUMIRA (534 patients)
AMLODIPINE BESYLATE (530 patients)
AREDIA (529 patients)
ZOLOFT (526 patients)
AUGMENTIN '125' (515 patients)
AMARYL (515 patients)
PERCOCET (514 patients)
ROCEPHIN (509 patients)
ACTOS (508 patients)
ETOPOSIDE (498 patients)
AVASTIN (495 patients)
PARACETAMOL (493 patients)
NAPROXEN (489 patients)
CLONIDINE (486 patients)
EXJADE (473 patients)
FAMOTIDINE (471 patients)
LEVOFLOXACIN (470 patients)
CLARITHROMYCIN (470 patients)
METOPROLOL SUCCINATE (467 patients)
GENTAMICIN (465 patients)
ZANTAC (464 patients)
CYTARABINE (464 patients)
CLOPIDOGREL (457 patients)
PREVISCAN (456 patients)
IRBESARTAN (454 patients)
TACROLIMUS (451 patients)
LEXAPRO (450 patients)
PEPCID (447 patients)
ADVAIR DISKUS 100/50 (447 patients)
LACTULOSE (444 patients)
VALSARTAN (443 patients)
SPIRIVA (443 patients)
MICARDIS (442 patients)
HUMALOG (440 patients)
RANITIDINE (439 patients)
PRADAXA (438 patients)
ARANESP (437 patients)
MULTI-VITAMINS (430 patients)
SOLU-MEDROL (430 patients)
DICLOFENAC SODIUM (428 patients)
ZETIA (427 patients)
JANUVIA (426 patients)
COLACE (424 patients)
VITAMIN B-12 (424 patients)
DIFLUCAN (422 patients)
NORVIR (420 patients)
OXALIPLATIN (412 patients)
BISOPROLOL (411 patients)
ZYPREXA (407 patients)
CLONAZEPAM (407 patients)
MAGNESIUM OXIDE (404 patients)
CALCIUM CARBONATE (399 patients)
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% (393 patients)
COMPAZINE (393 patients)
REGLAN (392 patients)
CALCIUM (390 patients)
CYMBALTA (389 patients)
METHYLPREDNISOLONE (388 patients)
COLCHICINE (386 patients)
LORTAB (385 patients)
CELLCEPT (384 patients)
PRAVASTATIN (384 patients)
NIFEDIPINE (382 patients)
VIREAD (382 patients)
ONDANSETRON (381 patients)
FENOFIBRATE (379 patients)
NYSTATIN (378 patients)
TYLENOL (374 patients)
GEMFIBROZIL (370 patients)
SODIUM BICARBONATE (368 patients)
ZOVIRAX (365 patients)
ISOSORBIDE MONONITRATE (364 patients)
DURAGESIC-100 (364 patients)
AZITHROMYCIN (363 patients)
DILTIAZEM (362 patients)
METOLAZONE (362 patients)
AMITRIPTYLINE HCL (361 patients)
MULTI-VITAMIN (361 patients)
GLICLAZIDE (361 patients)
LIDOCAINE (361 patients)
ZOLPIDEM (359 patients)
PLATELETS (359 patients)
ZESTRIL (357 patients)
PHOSPHOSODA FLAVOR NOT SPECIFIED (356 patients)
PAXIL (351 patients)
ZOSYN (346 patients)
ASCORBIC ACID (346 patients)
ATACAND (344 patients)
NOVOLOG (343 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about RENAL FAILURE ACUTE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.